In non-selected patients with advanced pancreatic cancer, a randomized, double-blind, placebo-controlled trial of trametinib in combination with gemcitabine recently failed to improve survival.[33] Lastly, a patient had a PR in a FIM with CHR-3996, a HDAC inhibitor. This evidence concerns the gene HDAC9 and familial pancreatic carcinoma.